Channel Therapeutics Corporation
New York Stock Exchange ArcaCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Francis Knuettel II,
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4400 Route 9 South Freehold NJ United States of America 07728
- IPO Date
- Feb 16, 2024
- CIK
- 0001919246
- Website
- channeltherapeutics.com
- Similar Companies
- Business
- Channel Therapeutics Corporation is a clinical-stage biotechnology company specializing in the development and commercialization of non-opioid, non-addictive therapeutics targeting pain management. The company’s core products focus on selective inhibition of the sodium ion channel NaV1.7, with key therapeutic programs including an oral treatment for neuropathic pain conditions such as idiopathic small fiber neuropathy and erythromelalgia; an eye drop formulation addressing acute and chronic eye pain; and a slow-release depot formulation for post-surgical nerve blocks. Channel Therapeutics operates primarily in the United States and centers on providing alternatives to opioid-based pain therapies, addressing systemic chronic pain, ocular pain, and post-operative nerve block indications. Founded in 2013 and headquartered in Freehold, New Jersey, Channel Therapeutics recently underwent significant corporate restructuring and strategic expansion. In 2024, the company reincorporated in Nevada following a merger with its wholly owned subsidiary and completed a 10-for-1 reverse stock split in July 2025 to meet NYSE American listing requirements. More notably, Channel Therapeutics merged with Pelthos Therapeutics in mid-2025, a transaction that brought $50.1 million in private placement funding and positioned the combined entity to launch Pelthos’ FDA-approved molluscum contagiosum treatment, ZELSUVMI™, expanding the company’s commercial-stage capabilities. The merger also resulted in leadership changes with Scott Plesha appointed as CEO and former Channel CEO Frank Knuettel II becoming CFO of the merged company. This strategic realignment significantly broadened the company’s portfolio and marked a shift toward commercial readiness alongside its clinical pipeline focused on the NaV1.7 channel. Channel Therapeutics continues to advance multiple clinical-stage programs with expected key data readouts in 2025 for its pain management drug candidates, while leveraging its deeper financial resources and expanded therapeutic reach through the Pelthos merger. The company targets orphan indications and niche markets to differentiate its non-opioid pain management therapies within a competitive pharmaceutical landscape.
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
Chromocell Announces Amendment to Stock Repurchase Plan
Chromocell to Participate in Life Sciences Investor Forum September 19th
Chromocell Announces Stock Repurchase Plan
Chromocell to Participate in the Virtual Investor Lunch Break Series
Paycom Announces Promotions of Randy Peck to COO, Jennifer Kraszewski to CHRO and Matt Paque to CLO
PROLOGIS' NEKRITZ AND MCKEOWN TO RETIRE; NEW CLO AND CHRO ANNOUNCED
Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024
Chromocell Issues Letter to Stockholders from Chief Executive Officer
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
Chromocell to Present at Sidoti Virtual Investor Conference March 13-14
Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions
Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million
U.S. IPO Weekly Recap: Nano-Caps Debut In Quiet Week